This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Fortrea Holdings Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM
Fortrea Holdings Completes Divestiture of Enabling Services Segment to Arsenal Capital Partners MT
Arsenal Capital Partners completed the acquisition of Fortrea Patient Access Inc., Endpoint Clinical, Inc. and Other Assets of Enabling Services Segment from Fortrea Holdings Inc.. CI
Fortrea Introduces Comprehensive Solution to Improve Diversity and Inclusion in Clinical Research CI
TD Cowen Starts Fortrea Holdings With Hold Rating, $27 Price Target MT
Mizuho Starts Fortrea Holdings With Neutral Rating, $27 Price Target MT
Some of the biggest splits in Corporate America RE
The latest transactions by star managers Our Logo
Fortrea Holdings Provides Information to the Shareholders CI
Fortrea Appoints Machelle Sanders to Board of Directors CI
Evercore ISI Adjusts Price Target on Fortrea to $31 From $43, Maintains Outperform Rating MT
Baird Upgrades Fortrea Holdings to Outperform Rating From Neutral, Adjusts Price Target to $36 From $45 MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Top Midday Decliners MT
Equities Mixed Intraday as Markets Analyze Consumer Inflation Survey MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Sector Update: Health Care MT
Fortrea Holdings Shares Fall After Swinging to Q1 Adjusted Loss MT
Fortrea Cuts Full-Year Revenue Outlook as First-Quarter Results Miss Views MT
Sector Update: Health Care Stocks Decline Pre-Bell Monday MT
Top Premarket Decliners MT
Transcript : Fortrea Holdings Inc., Q1 2024 Earnings Call, May 13, 2024
Fortrea Holdings Swings to Q1 Adjusted Loss, Revenue Falls; 2024 Revenue Outlook Cut MT
Stock Futures Rise Pre-Bell Ahead of Key Inflation Data; Asia, Europe Churn MT
Fortrea Holdings Inc. Reports Unaudited Consolidated Impairment Changes Results for the First Quarter Ended March 31, 2024 CI
Chart Fortrea Holdings Inc.
More charts
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
27.35 USD
Average target price
32.22 USD
Spread / Average Target
+17.81%
Consensus
  1. Stock Market
  2. Equities
  3. FTRE Stock
  4. News Fortrea Holdings Inc.
  5. Fortrea Holdings Expands Partnership With Medidata to Increase Diversity in Clinical Trials